Innovative Bispecific Nanobody Targeting ANGPT2 and VEGF for Autoimmune Disease Therapy

VHH-P464 is a humanized nanobody-based bispecific construct designed to target both angiopoietin 2 (ANGPT2) and vascular endothelial growth factors (VEGF). Currently in the Biological Testing stage, this program aims to provide a novel therapeutic approach for autoimmune disease. The antibody employs high-affinity single-domain antibodies (nanobodies) specific for ANGPT2 and VEGF, linked to constant domains for enhanced pharmacological properties. By simultaneously inhibiting these two key mediators of vascular biology, VHH-P464 holds promise for addressing the complex pathophysiology of autoimmune conditions, where aberrant angiogenesis and vascular dysfunction are recognized contributors to inflammation and tissue damage.

Licensing Opportunity

VHH-P464 is available for out-licensing partnerships. We actively seek collaborations with biopharmaceutical companies and research organizations to advance its clinical development and realize new therapeutic opportunities in autoimmune disease.

Development Phase

Modality

VHH-P464 is engineered as a bispecific antibody fusion composed of two distinct polypeptide chains, each targeting either VEGF or ANGPT2. The construct incorporates compact, single-domain antibody fragments, known for their small molecular size, high stability, and excellent tissue penetration. Inclusion of human IgG1 heavy chain and kappa light chain constant domains enhances its serum half-life and manufacturability, while the (G4S)3 linker confers structural flexibility and functional integrity. Expressed in ExpiCHO cells, this nanobody format offers advantages in crossing biological barriers and achieving deep tissue access, making it well-suited for the multifaceted pathology encountered in autoimmune disease.

Target

ANGPT2 and VEGF are critical protein targets involved in the regulation of angiogenesis and vascular permeability. ANGPT2, a ligand in the angiopoietin signaling axis, modulates vascular maturation and destabilization, predominantly expressed in endothelial tissues undergoing remodeling. VEGF, a key mediator of new blood vessel formation and inflammation, is well-characterized for its roles in vascular homeostasis and immune modulation, highly expressed in activated endothelial cells and inflamed tissues. Dysregulation of ANGPT2 and VEGF pathways contributes to the pathogenesis of autoimmune disease by promoting abnormal blood vessel growth and inflammatory cell infiltration. Targeting ANGPT2 and VEGF with VHH-P464 provides strategic leverage to disrupt these intersecting pathological signals, offering an innovative angle for therapeutic intervention and differentiation in the autoimmune disease market.

Mechanism of Action

VHH-P464 suppresses pathological angiogenesis and vascular leakage through simultaneous binding and neutralization of ANGPT2 and VEGF. As an angiogenesis inhibitor and signal transduction modulator, VHH-P464 interferes with receptor-mediated activation induced by ANGPT2 and VEGF, thus mitigating endothelial activation and downstream pro-inflammatory signaling cascades. By limiting new vessel formation and vascular permeability, VHH-P464 aims to reduce chronic inflammation, tissue edema, and immune cell infiltration characteristic of autoimmune disease. The nanobody platform’s modularity supports the development of next-generation therapeutics—such as bispecific, multispecific, or antibody-drug conjugate derivatives—expanding its clinical and commercial application potential.

Autoimmune Disease

Autoimmune diseases represent a diverse group of chronic disorders marked by immune-mediated attack against the body's own tissues, leading to inflammation, organ dysfunction, and significant morbidity. Globally, these conditions collectively impact millions and include common diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Standard treatments—ranging from immunosuppressive agents to targeted biologics—aim to reduce immune overactivity and manage symptoms, yet many patients still experience inadequate response, relapses, or adverse effects. There is considerable unmet need for safer, more effective therapies, particularly those capable of addressing the underlying mechanisms of disease progression. VHH-P464, by dual targeting of major vascular mediators ANGPT2 and VEGF, holds promise as a novel intervention, potentially improving clinical outcomes by not only dampening inflammation but also modulating pathological angiogenesis and tissue remodeling associated with autoimmune pathology.